Clinical Trial Update: Reduced-dosed Rivaroxaban in the Long-term Prevention of Recurrent Symptomatic VTE(Venous Thromboembolism) [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating reduced-dose rivaroxaban for long-term prevention of recurrent symptomatic venous thromboembolism following an initial VTE event; resul…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pulmonary Embolism
• Venous Thromboembolism

Drugs mentioned

• Rivaroxaban (rivaroxaban)

Snippet

Sponsor: Bayer | Conditions: Pulmonary Embolism, Thromboembolism | Phase 3 | Status: COMPLETED | Results posted: 2017-12-19